Cisplatin Potentiation of Radiotherapy: Long-term Follow-up
- 1 February 1985
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 111 (2) , 114-118
- https://doi.org/10.1001/archotol.1985.00800040078011
Abstract
• Thirty-three patients with inoperable squamous cell carcinoma of the head and neck were treated with cisplatin, 15 mg/sq m, administered synchronously with high-dose radiation therapy. Twenty-nine patients (88%) responded to the regimen; of these, 20 had complete regression of all disease. Eight of the 20 had a relapse in less than one year of their treatment. Among those patients who did not have a relapse, the follow-up period was short. It is concluded that a clinical regression response is more likely with this treatment regimen than with radiation therapy alone, and that that response may be a better palliation. Further study of this combination of treatment modalities is warranted. (Arch Otolaryngol 1985;111:114-118)This publication has 3 references indexed in Scilit:
- Cisplatin sensitization to radiotherapy of squamous cell carcinomas of the head and neckThe American Journal of Surgery, 1983
- Daily cis-dichlorodiammineplatinum (II) as a radio-enhancer: A preliminary toxicity reportZeitschrift für Krebsforschung und Klinische Onkologie, 1983
- Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II)International Journal of Radiation Oncology*Biology*Physics, 1979